Doug Kiehl
Senior Director Disruptive Transformative Technologies Team (Dt3) and Digital Twin Coe @Eli Lilly and Company
Signup · Get unlimited contacts
WORK HISTORY
Senior Director Disruptive Transformative Technologies Team (Dt3) and Digital Twin Coe @Eli Lilly and Company
Indianapolis, IN, US
The mission of DT3 is to explore, evaluate and align advanced technologies and capabilities to implement next-gen solutions and enable digital transformation (e.g, Pharma 4.0/5.0) across development and bioprocess. Our core capabilities include data analytics, automation, bioinformatics and cross-collaborative industry, academic and regulatory partnerships.\"All digital transformation, all the time\"- Established Lilly Digital Twin COE- Implementation of disruptive technologies to enable digital transformation for next-gen bioprocess, advanced manufacturing and product development- Pharma 4.0/5.0 strategic implementation- Digital Twin design/development, Entropy Minimized Digital Twin- Model explainability, interpretability- Purpose-driven AI- Global E&L strategy enabling development and qualification of packaging (container/closure) systems, drug delivery devices and manufacturing systems- Strategies for managing E&L and impurity assessment in change control, lifecycle management and supply chain integrity- Chair, Product Quality Research Institute (PQRI) Steering Committee- PhRMA Topic Leader for the ICH Q3E Expert Working Group, prior Rapporteur (2020)- USP General Chapters Packaging and Distribution Expert Committee- USP Expert Panel on Biocompatibility of Materials Used in Packaging Systems, Medical Devices and Implants- Board of Directors, Extractables/Leachables Safety Information Exchange (ELSIE) Consortium- Executive Governing Council, SEMI and Nano-Bio Materials Consortium- Application of advanced mass spectrometry and related techniques to provide innovative solutions to difficult problems involving the rapid and comprehensive assessment of impurities, contaminants and E&L, including chemical characterization supporting biocompatibility assessment- Development of novel mass mapping and visualization techniques for the rapid and comprehensive characterization of highly complex, structurally and compositionally diverse molecular mixtures
EDUCATION
New Mexico State University
Master's degree
SKILLS
ABOUT DOUG KIEHL
Senior Director at Eli Lilly and Company --Digital Transformation - Disruptive Technologies - Minimum Entropy Digital Twin - Purpose-Driven Digital Twin/AI - Pharma 4.0/5.0 - Exploring the Digital Event Horizon
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.